Cerebral small vessel disease
Conditions
Interventions
TMS+Drug therapy group:Transcranial magnetic stimulation (twice a day for 7 days, a total of 14 sessions, with stimulation at 40% intensity, inter-burst frequency of 37Hz, and inter-burst frequency of
Drug therapy group: Medication treatment according to the "Chinese Expert Consensus on the Diagnosis and Treatment of Cerebral Small Vessel Disease 2021" and based on individual circumstances, includi
Healthy control group:None
Sponsors
The First Affiliated Hospital of Dalian Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. Cerebral Small Vessel Disease (CSVD) Patient Group: (1) Meets the diagnostic criteria for CSVD according to the 2022 CSVD Guidelines; exhibits clinical manifestations of CSVD (e.g., cognitive impairment, gait disturbance, mood disorders, or urinary/bowel dysfunction), has relevant vascular risk factors, and shows one or more MRI features characteristic of CSVD; (2) Aged 18–85 years; (3) Able to cooperate with functional near-infrared spectroscopy (fNIRS) assessment and gait analysis walking tasks; (4) Modified Rankin Scale (mRS) score <= 3; (5) Provided written informed consent. 2. Healthy Control Group: (1) Healthy individuals without cerebral small vessel disease; (2) Aged 18–85 years; (3) Able to cooperate with relevant clinical scales, fNIRS assessment, and gait analysis walking tasks; (4) Provided written informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients with cerebral small vessel disease: (1) Acute phase of cerebral infarction caused by large-artery atherosclerosis, cardioembolism, cryptogenic sources, or other rare etiologies; (2) History of neurological disorders such as epilepsy, multiple sclerosis, Parkinson’s disease, or Alzheimer’s disease; (3) Psychiatric disorders such as schizophrenia or inability to cooperate with the study tasks; (4) History of traumatic brain injury, brain surgery, intracerebral hemorrhage, or severe systemic medical conditions; (5) Contraindications preventing completion of MRI examination; 2. Healthy control group: (1) Acute phase of cerebral infarction caused by large-artery atherosclerosis, cardioembolism, cryptogenic sources, or other rare etiologies; (2) History of neurological disorders such as epilepsy, multiple sclerosis, Parkinson’s disease, or Alzheimer’s disease; (3) Psychiatric disorders such as schizophrenia or inability to cooperate with the study tasks; (4) History of traumatic brain injury, brain surgery, intracerebral hemorrhage, or severe systemic medical conditions; (5) Contraindications preventing completion of MRI examination.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Functional near-infrared spectroscooy data;Eye tracking instrument data; | — |
Primary
| Measure | Time frame |
|---|---|
| Head MRI data;3-Meter Timed Up and Go Test;Gait status;Overall cognitive status;Emotional state;Assesses reaction speed and executive function.;Executive function;Attention;Language function;Visuospatial function, executive function, and writing ability;Visuospatial function;Urinary continence status;Activities of Daily Living ;Gait instrument data; | — |
Countries
China
Contacts
Public ContactZhang Bingwei
The First Affiliated Hospital of Dalian Medical University
Outcome results
None listed